0HX7 Stock Chart & Stats
$8.20
-$0.33(-4.02%)
At close: 4:00 PM EDT
$8.20
-$0.33(-4.02%)
Day’s Range― - ―
52-Week Range$3.70 - $13.89
Previous CloseN/A
Volume28.00
Average Volume (3M)3.39K
Market Cap
$35.67M
Enterprise Value-$12.49M
Total Cash (Recent Filing)$118.19M
Total Debt (Recent Filing)$12.85M
Price to Earnings (P/E)―
Beta1.80
Next Earnings
Nov 11, 2026EPS Estimate
-1.58Next Dividend Ex-DateN/A
Dividend Yield0.12%
Share Statistics
EPS (TTM)-11.45
Shares Outstanding9,361,490
10 Day Avg. Volume2,267
30 Day Avg. Volume3,391
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)0.36
Price to Sales (P/S)0.00
P/FCF Ratio-0.60
Enterprise Value/Market Cap-0.35
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit9.31
Enterprise Value/Ebitda0.13
Forecast
1Y Price Target
$25.00Price Target Upside204.88% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-6.36
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Early Clinical Efficacy And SafetyPrula-cel has produced encouraging Phase 1 lupus results, including renal responses and remission alongside a generally favorable safety profile. These findings support progression toward a pivotal trial and could strengthen the therapy’s potential to address autoimmune disease with a one-time treatment approach.
Off-the-Shelf Platform And PipelineThe company is building a broader allogeneic cell-therapy platform rather than relying on a single program. Prula-cel, ADI-212 and planned in vivo CAR-T studies provide multiple clinical development paths, creating opportunities for durable pipeline value if trials continue to validate the technology.
Conservative LeverageLow leverage reduces fixed financial obligations and provides more flexibility than a heavily debt-funded balance sheet. Although the company remains dependent on development funding, modest debt exposure limits interest and refinancing pressure while clinical programs advance through important milestones.
Bears Say
No Commercial Revenue And Persistent LossesAdicet has no meaningful product revenue because it remains a clinical-stage company without approved commercial therapies. Persistent large losses leave the business reliant on successful clinical development and future financing or partnerships rather than internally generated operating earnings.
Heavy Cash BurnSustained operating and free-cash-flow deficits indicate that ongoing research and clinical activity consumes substantial capital. Continued cash burn increases dependence on external funding and can constrain the pace of development or create dilution pressure before products generate revenue.
Shrinking Equity BaseThe substantial reduction in equity reflects the cumulative impact of sustained losses and cash consumption. A smaller capital base reduces financial resilience and may make future funding more consequential, particularly while the company remains pre-commercial and has significant clinical obligations.
Adicet Bio News
0HX7 FAQ
What was Adicet Bio Inc’s price range in the past 12 months?
Adicet Bio Inc lowest share price was $3.70 and its highest was $13.89 in the past 12 months.
What is Adicet Bio Inc’s market cap?
Adicet Bio Inc’s market cap is $35.67M.
When is Adicet Bio Inc’s upcoming earnings report date?
Adicet Bio Inc’s upcoming earnings report date is Nov 11, 2026 which is in 13 days.
How were Adicet Bio Inc’s earnings last quarter?
Adicet Bio Inc released its earnings results on Aug 05, 2026. The company reported -$1.99 earnings per share for the quarter, missing the consensus estimate of -$1.692 by -$0.298.
Is Adicet Bio Inc overvalued?
According to Wall Street analysts Adicet Bio Inc’s price is currently Undervalued.
Does Adicet Bio Inc pay dividends?
Adicet Bio Inc pays a Notavailable dividend of $0.285 which represents an annual dividend yield of 0.12%. See more information on Adicet Bio Inc dividends here
What is Adicet Bio Inc’s EPS estimate?
Adicet Bio Inc’s EPS estimate is -1.58.
How many shares outstanding does Adicet Bio Inc have?
Adicet Bio Inc has 9,361,490 shares outstanding.
What happened to Adicet Bio Inc’s price movement after its last earnings report?
Adicet Bio Inc reported an EPS of -$1.99 in its last earnings report, missing expectations of -$1.692. Following the earnings report the stock price went down -11.868%.
Which hedge fund is a major shareholder of Adicet Bio Inc?
Currently, no hedge funds are holding shares in GB:0HX7
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Adicet Bio Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$25.00 (204.88% Upside)
$25.00 (204.88% Upside)
Blogger Sentiment
Bullish
GB:0HX7 Sentiment 100%
Sector Average 65%
Sector Average 65%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-73.59%
12-Months-Change
Fundamentals
Return on Equity
-74.90%
Trailing 12-Months
Asset Growth
-9.08%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Adicet Bio Inc
Adicet Bio, Inc. is a biotechnology firm dedicated to pioneering allogeneic gamma delta T cell therapies, aiming to treat cancer and various other diseases. The company’s strategy involves engineering gamma delta T cells with chimeric antigen receptors (CARs) and T cell receptor-like antibodies. This advanced modification is designed to achieve more precise targeting of tumors, enhance the body's natural and acquired immune responses against cancer, and provide sustained therapeutic benefits for patients. ADI-001, its most advanced therapeutic candidate, is presently in a Phase I clinical trial for individuals with non-Hodgkin's lymphoma. Additionally, Adicet Bio is developing ADI-002, which is undergoing preclinical investigations for its potential in treating a range of solid tumors. The company is headquartered in Boston, Massachusetts.
0HX7 Stock 12 Month Forecast
Average Price Target
$25.00
▲(204.88% Upside)
Technical Analysis
Sutro Biopharma
―
PMV Pharmaceuticals
―
Gain Therapeutics
―
Immix Biopharma
―
Artiva Biotherapeutics, Inc.
―